Valuation: Nektar Therapeutics

Market Cap 2.38B 2.07B 1.94B 1.78B 3.35B 227B 3.41B 22.82B 8.94B 113B 8.96B 8.76B 374B P/E 2026 *
-7.83x
P/E 2027 * -6.51x
Enterprise Value 2.38B 2.07B 1.94B 1.78B 3.35B 227B 3.41B 22.82B 8.94B 113B 8.96B 8.76B 374B EV / Sales 2026 *
57.5x
EV / Sales 2027 * 64.5x
Free-Float
99.55%
Yield 2026 *
-
Yield 2027 * -
1 day+3.02%
1 week+2.11%
Current month+2.25%
1 month-1.22%
3 months-16.84%
6 months+91.98%
Current year+70.91%
1 week 67.11
Extreme 67.11
72.9
1 month 64.24
Extreme 64.24
77.23
Current year 33.4
Extreme 33.4
109
1 year 21.6
Extreme 21.6
109
3 years 6.19
Extreme 6.189
109
5 years 6.19
Extreme 6.189
290.55
10 years 6.19
Extreme 6.189
1,670.4
Manager TitleAgeSince
Chief Executive Officer 73 01/01/2007
Director of Finance/CFO 60 15/05/2026
Chief Tech/Sci/R&D Officer 52 01/07/2015
Director TitleAgeSince
Director/Board Member 72 01/08/2000
Chairman 69 01/05/1992
Director/Board Member 73 01/02/2007
Date Insider Type Main position Quantity % Market Cap.
7/24/26 A Free

Chief Technology Officer

16,500 0.0488%
7/24/26 A Free

Chief Executive Officer

57,200 0.1693%
6/30/26 A Sell

Chief Technology Officer

-5,681 0.0168%
Change 5-day change 1-year change 3-year change Capi.($)
+3.02%+2.11%+210.53%+804.49% 2.38B
+0.05%+3.08%+38.17%+66.77% 56.7B
+1.02%-5.49%+24.17%+63.00% 51.97B
+0.99%+0.14%-15.86%-13.06% 23.33B
+0.74%-5.12%-11.18%+349.30% 21.34B
+1.73%-1.49%+32.92%-25.74% 17.44B
+4.29%+1.67%+201.24%+344.48% 14.77B
+1.46%-1.24%+51.62%+175.33% 13.84B
+1.91%+1.43%+428.45%+174.91% 12.12B
+3.82%-7.09%+60.39%+157.39% 11.14B
Average +1.92%-1.40%+102.04%+209.69% 22.5B
Weighted average by Cap. +1.25%-1.41%+59.72%+120.28%

Financials

2026 *2027 *
Net sales 41.44M 36.02M 33.63M 30.87M 58.21M 3.95B 59.22M 397M 155M 1.97B 156M 152M 6.5B 36.99M 32.15M 30.01M 27.55M 51.95M 3.53B 52.86M 354M 139M 1.76B 139M 136M 5.8B
Net income -249M -217M -202M -186M -350M -23.75B -356M -2.38B -934M -11.84B -936M -915M -39.06B -351M -305M -285M -261M -493M -33.43B -501M -3.36B -1.31B -16.67B -1.32B -1.29B -54.99B
Net Debt - -
Logo Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Employees
63
Date Price Change Volume
04/08/26 $72.51 +2.72% 134,227
03/08/26 $70.59 -0.11% 611,868
31/07/26 $70.67 -1.09% 497,236
30/07/26 $71.45 +1.09% 676,759
29/07/26 $70.68 -0.13% 982,984
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
70.59USD
Average target price
153.22USD
Spread / Average Target
+117.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NKTR Stock